PriceTargets.com logo

Whitehawk Therapeutics - WHWK Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.56 As of 12/4/2025 05:00 PM ET
▲ +0.32 (14.29%)

This chart shows the closing price for WHWK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Whitehawk Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WHWK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WHWK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Whitehawk Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.56.

This chart shows the closing price for WHWK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 2 contributing investment analysts is to reduce stock in Whitehawk Therapeutics. This rating has held steady since October 2025, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/7/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/11/2025Zacks ResearchUpgradeStrong Sell
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Whitehawk Therapeutics logo
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More

Today's Range

Now: $2.56
Low: $2.23
High: $2.56

50 Day Range

MA: $2.20
Low: $1.90
High: $2.66

52 Week Range

Now: $2.56
Low: $1.39
High: $3.81

Volume

396,823 shs

Average Volume

189,229 shs

Market Capitalization

$120.65 million

P/E Ratio

18.29

Dividend Yield

N/A

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Whitehawk Therapeutics?

The following Wall Street research analysts have issued stock ratings on Whitehawk Therapeutics in the last year: Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for WHWK.

What is the current price target for Whitehawk Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Whitehawk Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Whitehawk Therapeutics in the next year.
View the latest price targets for WHWK.

What is the current consensus analyst rating for Whitehawk Therapeutics?

Whitehawk Therapeutics currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for WHWK.

What other companies compete with Whitehawk Therapeutics?

Other companies that are similar to Whitehawk Therapeutics include Canopy Growth, Kamada, PureTech Health, Alto Neuroscience and Solid Biosciences. Learn More about companies similar to Whitehawk Therapeutics.

How do I contact Whitehawk Therapeutics' investor relations team?

Whitehawk Therapeutics' physical mailing address is 17383 SUNSET AVENUE, SUITE A250, PACIFIC PALISADES, CA, 90272. The company's listed phone number is (424) 473-8055 and its investor relations email address is [email protected]. The official website for Whitehawk Therapeutics is aadibio.com. Learn More about contacing Whitehawk Therapeutics investor relations.